-
1Academic Journal
Source: Nauchno-prakticheskii zhurnal «Medicinskaia genetika». :10-16
Subject Terms: микроматричные исследования, copy number aberrations, BRCA1, PARP1, NF-κB, 3. Good health, microarray studies, 03 medical and health sciences, 0302 clinical medicine, breast cancer, прогноз, аберрации числа копий, prognosis, рак молочной железы, neoadjuvant chemotherapy, неоадъювантная химиотерапия
-
2Academic Journal
Authors: M. M. Tsyganov, M. K. Ibragimova, A. M. Pevzner, K. A. Gaptulbarova, E. Yu. Garbukov, Е. М. Slonimskaya, E. A. Usynin, N. V. Litviakov, М. М. Цыганов, М. К. Ибрагимова, А. М. Певзнер, К. А. Гаптулбарова, Е. Ю. Гарбуков, Е. М. Слонимская, Е. А. Усынин, Н. В. Литвяков
Contributors: This work was supported by grant number 18-29-09131 Russian Foundation for Basic Research “The phenomenon of tumor “fading” during chemotherapy”., Работа поддержана грантом Российского фонда фундаментальных исследований № 18-29-09131 «Феномен «замирания» опухоли в процессе химиотерапии».
Source: Advances in Molecular Oncology; Том 7, № 2 (2020); 29-38 ; Успехи молекулярной онкологии; Том 7, № 2 (2020); 29-38 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2020-7-2
Subject Terms: прогноз, microarray, transcript, ABC transporters, neoadjuvant chemotherapy, prognosis, микроматричные исследования, транскриптом, ABC-транспортеры, неоадъювантная химиотерапия
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/272/203; Семиглазов В.Ф., Горбунова В.А., Тюляндин С.А. Химиотерапия рака молочной железы: современный взгляд на проблему. Медицинский совет 2017;1(6):56–60. DOI:10.21518/2079-701X-2017-6-56-60 [Semiglazov V.F., Gorbunova V.A., Tjuljandin S.A. Chemotherapy for breast cancer: a modern view of the problem. Meditsinskiy sovet = Medical Advice 2017;1(6):56–60. (In Russ.)].; Parkinson A., Ogilvie B.W. Biotransformation of xenobiotics. Casarett and Doull’s toxicology: Basic Sci Poisons 2008;7(1):161–304.; Fletcher J.I., Haber M., Henderson M.J. et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10(2):147–56. DOI:10.1038/nrc278.9.; Litviakov N.V., Cherdyntseva N.V., Tsyganov M.M. et al. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer Chemother Pharmacol 2013;71(1):153–63. DOI:10.1007/s00280-012-1992-x.; Hlavata I., Mohelnikova-Duchonova B., Vaclavikova R. et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 2012;27(2):187–96. DOI:10.1093/mutage/ger075.; Patel A., Li T.W., Anreddy N. et al. Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacol Res 2017;121:184–93. DOI:10.1016/j.phrs.2017.04.025.; Литвяков Н.В., Гарбуков Е.Ю., Слонимская Е.М. и др. Связь безметастатической выживаемости больных раком молочной железы и вектора изменения экспрессии генов множественной лекарственной устойчивости в опухоли при проведении НХТ. Вопросы онкологии 2013;59(3):334–40. DOI: https://doi.org/10.18722/VO2013593334-340. [Litviakov N.V., Garbukov E.Yu., Slonimskaya E.M. et al. Connection of metastasis-free survival in breast cancer patients and an expression vector of multidrug resistance genes in tumor during neoadjuvant chemotherapy. Voprosy onkologii = Oncology Issues 2013;59(3):334–40. (In Russ.)].; Schwartz G.F., Hortobagyi G.N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Breast J 2004;10(4):273–94.; Irizarry R.A., Hobbs B., Collin F. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4(2): 249–64. DOI:10.1093/biostatistics/4.2.249.; Wind N., Holen I. Multidrug resistance in breast cancer – from in vitro models to clinical studies. Int J Breast Cancer 2011;2011:1–12. DOI:10.4061/2011/967419.; Kim B., Fatayer H., Hanby A.M. et al. Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS One 2013;8(5):1–8. DOI:10.1371/journal.pone.0062766.; Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007;1775(2):237–62. DOI:10.1016/j.bbcan.2007.05.002.; Velaei K., Samadi N., Soltani S. et al. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer. Breast Cancer 2017;24(4):552–61. DOI:10.1007/s12282-016-0738-8.; Patch A.M., Christie E.L., Etemadmoghadam D. et al. Wholegenome characterization of chemoresistant ovarian cancer. Nature 2015;521(7553): 489–94. DOI:10.1038/nature14410.; Wilson C.S., Davidson G.S., Martin S.B. et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006;108(2):685–96. DOI:10.1182/blood-2004-12-4633.; Steinbach D., Gillet J.P., Sauerbrey A. et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006;12(14):4357–63. DOI:10.1158/1078-0432.CCR-05-2587.; Chen Z., Shi T., Zhang L. et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 2016;370(1):153–64. DOI:10.1016/j.canlet.2015.10.010.; Fung S.W., Cheung P.F.Y., Yip C.W. et al. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Lett 2019;457:98–109. DOI:10.1016/j.canlet.2019.05.010.; Elsnerova K., MohelnikovaDuchonova B., Cerovska E. et al. Gene expression of membrane transporters: importance for prognosis and progression of ovarian carcinoma. Oncol Rep 2016;35(4):2159–70. DOI:10.3892/or.2016.4599.; Huang J.F., Wen C.J., Zhao G.Z. et al. Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. Cancer Chemother Pharmacol 2018;82(2):199–210. DOI:10.1007/s00280-018-3603-y.; Hu H., Wang M., Guan X. et al. Loss of ABCB4 attenuates the caspasedependent apoptosis regulating resistance to 5-Fu in colorectal cancer. Biosci Rep 2018;38(1):BSR20171428. DOI:10.1042/BSR20171428.; Hontecillas-Prieto L., GarciaDominguez D.J., Vaca D.P. et al. Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients. Oncotarget 2017;8(7):11173–86. DOI:10.18632/oncotarget.14491.; Tulsyan S., Mittal R.D., Mittal B. The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmacogen Personal Med 2016;9(1):47–58. DOI:10.2147/PGPM.S86672.; Kim H.J., Im S.A., Keam B. et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 2015;106(1): 86–93. DOI:10.1111/cas.12560.; https://umo.abvpress.ru/jour/article/view/272
-
3Academic Journal
Authors: M. M. Tsyganov, M. K. Ibragimova, A. M. Pevzner, E. Yu. Garbukov, K. A. Gaptulbarova, E. M. Slonimskaya, N. V. Litviakov, М. М. Цыганов, М. К. Ибрагимова, А. М. Певзнер, Е. Ю. Гарбуков, К. А. Гаптулбарова, Е. М. Слонимская, Н. В. Литвяков
Source: Medical Genetics; Том 19, № 6 (2020); 29-30 ; Медицинская генетика; Том 19, № 6 (2020); 29-30 ; 2073-7998
Subject Terms: прогноз, microarray studies, BRCA1, PARP1, NF-κB, copy number aberrations, neoadjuvant chemotherapy, prognosis, микроматричные исследования, аберрации числа копий, неоадъювантная химиотерапия
File Description: application/pdf
Availability: https://www.medgen-journal.ru/jour/article/view/1390
-
4Academic Journal
Authors: M. M. Tsyganov, I. V. Deryusheva, E. Yu. Garbukov, M. K. Ibragimova, P. V. Kazantseva, V. A. Bychkov, E. M. Slonimskaya, N. V. Litviakov
Source: Бюллетень сибирской медицины, Vol 16, Iss 4, Pp 250-259 (2018)
Subject Terms: потеря гетерозиготности, рак молочной железы, гены монорезистентности, микроматричные исследования, Medicine
Relation: https://bulletin.ssmu.ru/jour/article/view/1042; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/7dc7c0e244b64d05b60f54552c6a581d
-
5Academic Journal
Authors: M. M. Tsyganov, M. K. Ibragimova, I. V. Deryusheva, N. V. Litviakov, М. М. Цыганов, М. К. Ибрагимова, И. В. Дерюшева, Н. В. Литвяков
Source: Medical Genetics; Том 16, № 1 (2017); 25-30 ; Медицинская генетика; Том 16, № 1 (2017); 25-30 ; 2073-7998
Subject Terms: neoadjuvant chemotherapy, микроматричные исследования, однонуклеотидные полиморфизмы, семейство генов ABC-транспортеров, неоадъювантная химиотерапия, breast cancer, microarray, single nucleotide polymorphisms, ATP-binding cassette genes family
File Description: application/pdf
Relation: https://www.medgen-journal.ru/jour/article/view/226/188; Wind N, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. International journal of breast cancer. 2011;2011:1-12.; Litviakov NV, Cherdyntseva NV, Tsyganov MM, Denisov EV, Garbukov EY, Merzliakova MK, Volkomorov VV, Vtorushin SV, Zavyalova MV, Slonimskaya EM. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer chemotherapy and pharmacology. 2013;71(1):153-163.; Litviakov NV. Gradient phenomenon of multidrug resistance gene expression in breast cancer during neoadjuvant chemotherapy is related to disease progression. Siberian journal of oncology. 2013(4):58.; Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P, Ralhan R. CpG hypomethylation of< i> MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clinical biochemistry. 2010;43(4):373-379.; Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer gene therapy. 2010;17(8):523-531.; Sui H, Fan Z, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. Journal of International Medical Research. 2012;40(2):426-435.; Di Francia R, Siesto R, Valente D, Spart D, Berretta M. Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy. Eur Rev Med Pharmacol Sci. 2012;16(9):1211-1217.; Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res. 2010;9(1):34-40.; Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. The Breast Journal. 2004;10(4):273-294.; Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research. 2001;29(9):e45-e45.; Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer science. 2015;106(1):86-93.; Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. Journal of Pharmacology and Experimental Therapeutics. 2001;297(3):1137-1143.; Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. The pharmacogenomics journal. 2010;10(1):62-69.; Chen Z, Le H, Zhang Y, Qian L, Sekhar KR, Li W. Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. Journal of International Medical Research. 2011;39(5):1693-1700.; Vulsteke C, Lambrechts D, Dieudonne A, Hatse S, Brouwers B, Van Brussel T, Neven P, Belmans A, Schoffski P, Paridaens R. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Annals of Oncology. 2013;24(6):1513-1525.; Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. Journal of Clinical Oncology. 2010;28(8):1287-1293.; Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clinical chemistry. 2009;55(10):1770-1782.; Chen S, Villeneuve L, Jonker D, Couture F, Laverdiere I, Cecchin E, Innocenti F, Toffoli G, Levesque E, Guillemette C. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenetics and Genomics. 2015;25(12): 573-583.; Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmacogenomics and personalized medicine. 2014; 7: 53-64.; Sun S, Shi W, Wu Z, Zhang G, Yang B, Jiao S. Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer. Experimental and therapeutic medicine. 2015;10(3):937-941.
Availability: https://www.medgen-journal.ru/jour/article/view/226